Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphatic Dysfunction, Leukotrienes, and Lymphedema.

Xinguo Jiang1,2, Mark R Nicolls1,2, Wen Tian1,2

  • 1VA Palo Alto Health Care System, Palo Alto, California 94304, USA.

Annual Review of Physiology
|October 15, 2017
PubMed
Summary

Leukotriene B4 (LTB4), an inflammatory mediator, plays a key role in lymphedema development. Understanding LTB4

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Power and sample-size estimation in human microbiome research.

Med (New York, N.Y.)·2026
Same author

Hypoxia Induces Adaptive Lymphangiogenesis via Cd74 and Vegfr3 to Modulate Pulmonary Hypertension.

Circulation research·2026
Same author

CES1 deficiency is associated with metabolic reprograming and endothelial dysfunction in pulmonary arterial hypertension.

American journal of respiratory and critical care medicine·2026
Same author

Correction to: Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension.

Circulation research·2026
Same author

Redefining the Diagnostic Threshold for Breast Cancer-related Lymphedema.

Annals of surgery·2025
Same author

APOA1 binding protein promotes lymphatic cell fate and lymphangiogenesis by relieving caveolae-mediated inhibition of VEGFR3 signaling.

Nature communications·2025

Area of Science:

  • Lymphatic system biology and disease
  • Inflammatory mediator pathways
  • Molecular pathogenesis of lymphedema

Background:

  • The lymphatic system is crucial for fluid balance, lipid absorption, and immune cell transport.
  • While lymphatic regeneration aids healing, abnormal lymphangiogenesis contributes to diseases like lymphedema, atherosclerosis, and cancer.
  • Chronic inflammation can disrupt lymphatic function, necessitating research into therapeutic strategies.

Purpose of the Study:

  • To review lymphatic development and the pathophysiology of lymphedema.
  • To elucidate the role of leukotrienes, specifically leukotriene B4 (LTB4), in lymphedema.
  • To highlight the need for therapeutics targeting lymphatic dysfunction.

Main Methods:

  • Literature review of lymphatic development and lymphedema pathophysiology.
Keywords:
5-lipoxygenaseleukotriene B4lymphedema

Related Experiment Videos

  • Analysis of the role of inflammatory mediators in disease.
  • Focus on the molecular mechanisms involving leukotriene B4 (LTB4).

    • Main Results:

    • Lymphatic dysfunction is linked to pathological lymphangiogenesis in chronic diseases.
    • Leukotriene B4 (LTB4), an innate immune product, is implicated in lymphedema pathogenesis.
    • LTB4 is identified as a key molecular player in the inflammatory processes driving lymphedema.

    Conclusions:

    • Understanding the inflammatory pathways, particularly involving leukotrienes, is vital for treating lymphedema.
    • Targeting leukotriene B4 (LTB4) may offer a novel therapeutic approach for reversing lymphatic dysfunction.
    • Further research is needed to develop treatments for primary and acquired lymphatic disorders.